China NMPA Drug Inspection - Chongqing Sanlitang Traditional Chinese Medicine Pharmaceutical Co., Ltd. - Polygonatum
China NMPA drug inspection for Chongqing Sanlitang Traditional Chinese Medicine Pharmaceutical Co., Ltd. published July 23, 2020. Drug: Polygonatum. In July 2020, the National Medical Products Administration (NMPA) of China issued Announcement No. 50, identifying 25 ba
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Chongqing Sanlitang Traditional Chinese Medicine Pharmaceutical Co., Ltd. published July 23, 2020. Drug: Polygonatum. In July 2020, the National Medical Products Administration (NMPA) of China issued Announcement No. 50, identifying 25 ba
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox